Drug Type AAV based gene therapy |
Synonyms AAV2-SFLT01, GZ-402663, SFLT-01 |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Age Related Macular Degeneration | Phase 1 | US | 11 Jan 2010 | |
Retinal Neovascularization | Phase 1 | US | 11 Jan 2010 | |
Dystrophy, Macular | Phase 1 | US | 02 Dec 2009 | |
Neoplasms | Discovery | US | 16 Nov 2009 | |
Blindness | Discovery | US | 16 May 2006 |
Not Applicable | VEGF | - | AAV2.Flt23k | bsnydophut(gfsxafirbb) = wcocnzykpb zjnfmcvenn (zypzsqapki, 0.02) | Positive | 01 Jul 2018 | |
bsnydophut(gfsxafirbb) = gssfaapnut zjnfmcvenn (zypzsqapki, 0.03) | |||||||
Phase 1 | 19 | AAV2-sFLT01 2×10^8 vg | djkvlqanfr(izdbrmilho) = ytwfgjgllj efjvsebhfn (nrvszvexko ) | Positive | 01 May 2016 |